Results from a clinical trial evaluating the efficacy of real-time body surface visual feedback in reducing patient motion during lung cancer radiotherapy by Gareth J. Price (2166580)

“…</p> <p><b>Method and materials:</b> Fourteen lung cancer patients were enrolled in a prospective clinical study and asked to use a variety of visual feedback schema from a novel in-house developed optical surface measurement device. …”

Glucose depletion decreases SBPM. by David S. Tourigny (7224299)

“…<b>C)</b> Only the metabolically active D-isoform of glucose (not L-glucose) can sustain a significantly higher SBPM in physiologically-relevant conditions containing 5mM D- or L-glucose, 5mM DL-lactate (racemic mixture) and 0.22mM pyruvate. …”

Thalidomide treatment inhibits growth in RAMEC but not in RAMEC transfected with a dominant negative mutant of CUL5 (^S730ACUL5) cDNA. by Bryan Kunkler (5204327)

Rapamycin decreases phosphorylation of S6. by Adam L. Hartman (308128)

HDL decreases endothelial exocytosis. by Scott J. Cameron (838315)

Models of G48D, M78I, G125C, and A146V RAD52 point mutants. by Abdulaziz B. Hamid (13804692)

Effect of lysosomal hydrolysis inhibition on the decrease of PrP^Sc levels induced by CPZ or U18666A treatment. by Takeshi Yamasaki (521196)

Supplemental Figure 5: UAB30 decreased tumor growth in SK-NEP-1 xenografts. from Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies by Alicia M. Waters (9314636)

MTM decreased angiogenic response. by Eléonore Otjacques (410361)

“…<p>CD31 immuno-staining on bone marrow sections of control mice (<b>A</b>) or 5TGM1 injected mice, treated with the vehicle solution (<b>B</b>) or with MTM (<b>C</b>). …”

Weighted odds ratios reflecting the impact of a genetically determined 10 mg/dL decrease in LDL-C on safety and efficacy endpoints. by Aeron M. Small (9617751)

“…<p>Odds ratio and 95% confidence interval is displayed for the effect of a genetically determined 10 mg/dL decrease in LDL-C on safety and efficacy endpoints for White individuals, Black individuals, Hispanic individuals, and inverse variance weighted meta-analysis of White, Black, and Hispanic populations (IVWMA). …”

Decreased 5-Hydroxymethylcytosine Is Associated with Neural Progenitor Phenotype in Normal Brain and Shorter Survival in Malignant Glioma by Brent A. Orr (150119)

Treatment with a highly reducing agent decreases ubiquitination of D_4.2R WT and D_{4.2 4KR}R mutant. by Kamila Skieterska (841014)

Decreased dCAP-D3 expression results in double strand break accumulation within retrotransposon sequence. by Andrew T. Schuster (478446)

Δ3C virus-induced lymphomas have decreased expression of E2F target genes. by James C. Romero-Masters (4112614)

Cardamonin inhibited tumor growth and decreased FASN and Raptor. by Peiguang Niu (17044532)

“…(C) Immunohistochemistry staining of Ki-67, Raptor and FASN in the xenograft tumor tissues. Scale bar: 40 μm. (D) The semiquantification of Ki-67, Raptor and FASN in the tumor tissues (<i>n = 5</i>). …”

AA-deficient <i>sfx</i> mice had decreased articular cartilage. by Richard C. Lindsey (7148168)

Doxorubicin decreased the adiponectin levels. by Luana Amorim Biondo (2576386)

TUDCA decreases ER stress in HOX neonatal rat lungs. by Kirkwood A. Pritchard Jr. (13449794)

“…<p>(<b>A</b>) The expression levels of ER stress markers (P-PERK 0.6±0.1-fold, p<0.001, n = 5; PERK 0.7±0.1-fold, p = 0.00364, n = 5; P-IRE1α 0.6±0.0-fold, p<0.001, n = 5; IRE1α 0.6±0.1-fold, p<0.001, n = 5; GRP78 0.8±0.1-fold, p<0.001, n = 5; cleaved ATF6 0.1±0.0-fold, p<0.001, n = 5; spliced XBP1 0.3±0.0-fold, p<0.001, n = 5; 2 males and 3 females) are all decreased while the N-glycosylated VEGFR2 is increased (3.5±0.2-fold, p<0.001, n = 5) in HOX neonatal lungs at P10 indicating TUDCA can attenuate hyperoxia-induced ER stress. …”

FoxO3a-dependent mechanism of miR-150-5p in regulating pyroptosis in ox-LDL-stimulated RAW264.7 macrophages. (A-E) FoxO3a and ARC expression analyzed by (A-C) RT-qPCR and (D-E) Wes... by Ping-yu Cai (12389929)

Subjects:

Decreased Aβ oligomer immunoreactivity in APPxPS1 mice after treatment with hNGFP61S/R100E: scFV A13 antibody. by Simona Capsoni (161132)